Friday, 16 October 2026European Markets

CBO TERRITORIA And NEXTENSA Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - cbo territoria (cbot.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
cbo territoria (cbot.pa) €3.71 6.45% 5.88%
nextensa (nexta.br) €46.15 3.23% 2.86%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. cbo territoria (cbot.pa)

6.45% forward dividend yield and 5.88% return on equity

cbo territoria sa engages in the urban planning and development, and property development and investment activities in france. the company develops and sells housings, retail parks, offices, industrial premises, shops, plots of land, business premises, and warehouses. it is also involved in the leisure, catering, marketing, and coworking businesses. cbo territoria sa was incorporated in 2004 and is headquartered in sainte-marie, france.

earnings per share

as for profitability, cbo territoria has a trailing twelve months eps of €0.43.

pe ratio

cbo territoria has a trailing twelve months price to earnings ratio of 8.63. meaning, the purchaser of the share is investing €8.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.88%.

more news about cbo territoria.

2. nextensa (nexta.br)

3.23% forward dividend yield and 2.86% return on equity

nextensa is a mixed-use real estate investor and developer. the company's investment portfolio is divided between the grand duchy of luxembourg (43%), belgium (42%) and austria (15%); its total value as at 31/12/2023 was approximately € 1.3 billion. as a developer, nextensa is primarily active in shaping large urban developments. at tour & taxis (development of over 350,000 sqm) in brussels, nextensa is building a mixed real estate portfolio consisting of a revaluation of iconic buildings and new constructions. in luxembourg (cloche d'or), it is working in partnership on a major urban extension of more than 400,000 sqm consisting of offices, retail and residential buildings. the company is listed on euronext brussels and has a market capitalisation of € 488.6 m (value 31/12/2023).

earnings per share

as for profitability, nextensa has a trailing twelve months eps of €2.47.

pe ratio

nextensa has a trailing twelve months price to earnings ratio of 18.68. meaning, the purchaser of the share is investing €18.68 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.86%.

revenue growth

year-on-year quarterly revenue growth declined by 39.8%, now sitting on 120.11m for the twelve trailing months.

volume

today's last reported volume for nextensa is 113 which is 90.63% below its average volume of 1207.

moving average

nextensa's worth is above its 50-day moving average of €44.50 and below its 200-day moving average of €46.17.

more news about nextensa.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com